Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Cancer Epidemiol. 2011 Dec;35(6):545-50. doi: 10.1016/j.canep.2011.02.008. Epub 2011 Apr 5.
The aim of this study was to examine whether screening exposure status, defined as detection mode (screening, interval or symptomatic) combined with breast cancer screening attendance prior to diagnosis, had any additional value over detection mode in predicting breast cancer survival. We also assessed the effect of hormone replacement therapy (HRT) on the association of detection mode with breast cancer survival.
We analysed and compared the associations of both screening exposure status and detection mode with 5-year breast cancer survival on a cohort of 3013 breast cancer patients, aged 50-74 years in Sweden. We used Cox proportional hazards modelling with adjustments for tumour size, grade, estrogen receptor (ER) and progesterone receptor (PR) status and lymph node involvement. We repeated the analyses after stratification for HRT use.
Multivariate hazard ratios (HR) for cancers detected in patients at subsequent screens, interval cancers and symptomatic cancers in patients with and without previous screening attendance were 1.3 (95%CI 0.7-2.3), 1.8 (95%CI 1.0-3.2), 1.8 (95%CI 0.9-3.6) and 2.2 (95%CI 1.2-4.1) respectively, compared with cancers detected at the first screen. The regression model including screening exposure status had no additional prognostic value over the model including detection mode (P=0.63). HRT users showed a more favourable survival than non-users; this was not influenced by detection mode.
The number of routine screening examinations attended in the 5-year period prior to diagnosis had no additional prognostic value over detection mode in predicting breast cancer survival.
本研究旨在探讨在预测乳腺癌生存方面,筛查暴露状态(定义为检测模式[筛查、间隔或症状性]与诊断前的乳腺癌筛查参与情况相结合)是否比检测模式具有额外价值。我们还评估了激素替代疗法(HRT)对检测模式与乳腺癌生存之间关联的影响。
我们分析并比较了 3013 例瑞典 50-74 岁乳腺癌患者的筛查暴露状态和检测模式与 5 年乳腺癌生存的关联。我们使用 Cox 比例风险模型,对肿瘤大小、分级、雌激素受体(ER)和孕激素受体(PR)状态以及淋巴结受累情况进行了调整。我们在分层 HRT 使用情况后重复了分析。
在有或没有既往筛查参与的患者中,后续筛查、间隔期癌症和症状性癌症中检测到的癌症的多变量危险比(HR)分别为 1.3(95%CI 0.7-2.3)、1.8(95%CI 1.0-3.2)、1.8(95%CI 0.9-3.6)和 2.2(95%CI 1.2-4.1),与首次筛查中检测到的癌症相比。包括筛查暴露状态的回归模型与包括检测模式的模型相比,没有额外的预后价值(P=0.63)。HRT 使用者的生存情况优于非使用者;这不受检测模式的影响。
在诊断前的 5 年内接受的常规筛查检查次数与预测乳腺癌生存方面,没有比检测模式具有额外的预后价值。